ANI Pharmaceuticals, Inc.
NASDAQ:ANIPDrug Manufacturers - Specialty & Generic
-$1.42 today
- Market cap
- $1.62B
- Beta
- 0.44
- P/E (TTM)
- 18.5
- EPS (TTM)
- $4.29
Volume 0.29M
Average 0.35M
ANIP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ANI Pharmaceuticals, Inc.NASDAQ: ANIP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $10.6M rose 0.3% year over year, behind the +15.8% change in trailing-twelve-month research & development. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at +32.3% a year.
Context
- Research & development amounted to 5.8% of revenue in FY2025, down 1.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.3% toward the trailing-twelve-month pace of +15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 51.66M USD
- Year-over-year change
- +15.9%
- 4-year CAGR
- +46.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.66M | +15.9% |
| FY2024 | 2024-12-31 | 44.58M | +30.0% |
| FY2023 | 2023-12-31 | 34.29M | +53.6% |
| FY2022 | 2022-12-31 | 22.32M | +96.3% |
| FY2021 | 2021-12-31 | 11.37M | — |
Research & Development vs competitors
How ANIP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.8% is the 4th highest of 9, against a peer median of +2.2%.
- Research & development amounts to 5.6% of revenue for ANIP, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹22.73B INR | -13.8% | +9.3% | 6.9% | |
| LTM Jun 2026 | $1.02B USD | +20.8% | +13.4% | 6.9% | |
| LTM Jun 2026 | $995M USD | -0.7% | +6.5% | 5.7% | |
| LTM Jun 2026 | $634M USD | +1.3% | +5.9% | 5.8% | |
| LTM Jun 2026 | $177.66M USD | -15.0% | -3.7% | 5.7% | |
| LTM Mar 2026 | $92.49M USD | +20.2% | +4.7% | 12.8% | |
| LTM Mar 2026 | $51.7M USD | +15.8% | +32.3% | 5.6% | |
| LTM Mar 2026 | $15.36M USD | +17.2% | +61.5% | 5.7% | |
| LTM Mar 2026 | $9.6M USD | +3.2% | +12.4% | 3.2% | |
| LTM Mar 2026 | $7.58M USD | — | +1.8% | 5.6% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ANIP) | — | +2.2% | +6.5% | 5.7% | |
Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 216.14M | 316.39M | 486.82M | 614.38M | 883.37M |
| Cost of Revenue | 100.61M | 138.79M | 181.51M | 250.21M | 432.73M |
| Gross Profit | 115.53M | 177.6M | 305.3M | 364.17M | 450.64M |
| Gross Margin | 53.5% | 56.1% | 62.7% | 59.3% | 51.0% |
| Research & Development | 11.37M | 22.32M | 34.29M | 44.58M | 51.66M |
| Selling, General & Admin | 84.29M | 124.04M | 161.7M | 249.64M | 317.75M |
| Operating Expenses | 155.32M | 212.88M | 258.33M | 363.58M | 369.41M |
| Depreciation & Amortization | 47.25M | 59.65M | 59.79M | 67.73M | 91.42M |
| EBITDA | 3.12M | 25.04M | 106.6M | 63.12M | 207.27M |
| EBITDA Margin | 1.4% | 7.9% | 21.9% | 10.3% | 23.5% |
| Operating Income | (39.79M) | (35.28M) | 46.97M | 584K | 81.23M |
| Operating Margin | -18.4% | -11.2% | 9.6% | 0.1% | 9.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.92M | 28.05M | 26.94M | 17.6M | 20.06M |
| Other Income / Expenses | (16.27M) | (27.38M) | (27.1M) | (22.8M) | 14.56M |
| Income Before Tax | (56.06M) | (62.67M) | 19.87M | (22.21M) | 95.79M |
| Pre-Tax Margin | -25.9% | -19.8% | 4.1% | -3.6% | 10.8% |
| Income Tax Expense | (13.46M) | (14.77M) | 1.09M | (3.69M) | 17.45M |
| Net Income | (42.6M) | (47.9M) | 18.78M | (18.52M) | 78.34M |
| Net Margin | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% |
| EPS (Basic) | (3.40) | (3.05) | 0.95 | (1.04) | 3.50 |
| EPS (Diluted) | (3.40) | (3.05) | 0.94 | (1.04) | 3.32 |
| Weighted Avg Shares | 12.6M | 16.26M | 18M | 19.32M | 20.05M |
| Weighted Avg Shares (Diluted) | 12.6M | 16.26M | 18.19M | 19.32M | 21.23M |
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
Intrinsic Alpha fair value
Locked
Current Price
$71.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.